Business Context and Reporting Period
CytomX Therapeutics, Inc. (CTMX) filed a Current Report on Form 8-K on May 12, 2025, reporting a significant capital raise event. The company, incorporated in Delaware and headquartered in South San Francisco, operates in the biotechnology sector.
Key Financial Metrics
This filing details a primary equity offering rather than periodic financial performance metrics. Key transaction figures include:
- Shares Issued: 76,923,076 shares of Common Stock.
- Offering Price: $1.30 per share.
- Estimated Net Proceeds: Approximately $93.4 million (after underwriting discounts, commissions, and estimated offering expenses).
- Closing Date: May 13, 2025.
- Underwriters: Jefferies LLC and Piper Sandler & Co.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels, as this is an event-driven report.
Material Changes
The material change reported is the substantial increase in the company's share count and cash liquidity resulting from the underwritten public offering. The company intends to utilize the net proceeds for research and development, general corporate purposes, and working capital needs.
Guidance, Outlook, and Risks
Management commentary is limited to the intended use of proceeds. The filing notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. No specific forward-looking guidance on clinical milestones or financial projections is included in this document.
Investor Verification Checklist
- Verify the final closing price and total net proceeds in the subsequent Form 10-Q or 10-K.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or registration rights.
- Assess the dilution impact of the 76.9 million new shares on existing shareholders.
- Monitor future filings for updates on the allocation of the $93.4 million toward specific R&D programs.